From the Journals

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.

Share

The BE RADIANT clinical trial evaluated the efficacy of bimekizumab in treating moderate to severe plaque psoriasis over three years. Involving 743 patients, it compared bimekizumab (320 mg) and secukinumab (300 mg) across a 48-week double-blind treatment period followed by a 96-week open-label extension. Significant improvements in symptoms and quality of life were observed as early as week 4 and maintained through year three for patients on bimekizumab, with better outcomes in key measures compared to secukinumab, highlighting its long-term benefits.

Original Source(s)

Bimekizumab in Psoriasis: 3-Year Outcomes

  • by Kathryn Wighton

  • March 12, 2026

Related Content

HS Linked to Higher Self-Harm, Suicide Risk

Prior self-harm episodes and nonviolent methods are more common among HS patients who die by suicide, new research finds.

Dual-Frequency Radiofrequency for Facial Laxity?

Investigators report high 90-day response rates with no persistent adverse events.

Dupilumab Faces Trial in Chronic Hives

Phase III CUPID-C trial evaluates biologic therapy in patients with chronic spontaneous urticaria uncontrolled by antihistamines.